SG10201608071YA - Biologically active peptides - Google Patents

Biologically active peptides

Info

Publication number
SG10201608071YA
SG10201608071YA SG10201608071YA SG10201608071YA SG10201608071YA SG 10201608071Y A SG10201608071Y A SG 10201608071YA SG 10201608071Y A SG10201608071Y A SG 10201608071YA SG 10201608071Y A SG10201608071Y A SG 10201608071YA SG 10201608071Y A SG10201608071Y A SG 10201608071YA
Authority
SG
Singapore
Prior art keywords
biologically active
active peptides
peptides
biologically
active
Prior art date
Application number
SG10201608071YA
Other languages
English (en)
Inventor
Friedrich Scheiflinger
Michael Dockal
Original Assignee
Baxter Int
Baxter Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Int, Baxter Healthcare Sa filed Critical Baxter Int
Publication of SG10201608071YA publication Critical patent/SG10201608071YA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • C07K14/755Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64Cyclic peptides containing only normal peptide links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
SG10201608071YA 2008-04-17 2009-04-16 Biologically active peptides SG10201608071YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US932608P 2008-04-17 2008-04-17
US11305508P 2008-11-10 2008-11-10

Publications (1)

Publication Number Publication Date
SG10201608071YA true SG10201608071YA (en) 2016-11-29

Family

ID=40887122

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201809286XA SG10201809286XA (en) 2008-04-17 2009-04-16 Biologically active peptides
SG10201608071YA SG10201608071YA (en) 2008-04-17 2009-04-16 Biologically active peptides

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201809286XA SG10201809286XA (en) 2008-04-17 2009-04-16 Biologically active peptides

Country Status (19)

Country Link
US (6) US8563688B2 (ru)
EP (2) EP3115370B1 (ru)
JP (3) JP6038452B2 (ru)
KR (2) KR101606248B1 (ru)
CN (2) CN105524163A (ru)
AR (1) AR071478A1 (ru)
AU (1) AU2009244635B2 (ru)
BR (1) BRPI0911203A2 (ru)
CA (1) CA2721694C (ru)
DK (2) DK2279200T3 (ru)
ES (2) ES2594706T3 (ru)
HK (2) HK1154255A1 (ru)
MX (1) MX2010011397A (ru)
NZ (1) NZ588200A (ru)
PL (1) PL2279200T3 (ru)
PT (1) PT2279200T (ru)
SG (2) SG10201809286XA (ru)
TW (2) TWI573806B (ru)
WO (1) WO2009137256A1 (ru)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR071478A1 (es) * 2008-04-17 2010-06-23 Baxter Healthcare Sa Peptidos de bajo peso molecular con actividad procoagulante para el tratamiento de pacientes con deficiencia de factor v (fv), fvii, fviii, fx y/o fxi
CA2772051C (en) 2009-08-24 2020-08-18 Amunix Operating Inc. Coagulation factor ix compositions and methods of making and using same
WO2012012444A2 (en) 2010-07-19 2012-01-26 Dolby Laboratories Licensing Corporation Enhancement methods for sampled and multiplexed image and video data
PT2717898T (pt) 2011-06-10 2019-05-20 Bioverativ Therapeutics Inc Compostos pró-coagulantes e processos para a sua utilização
NZ628014A (en) 2012-02-15 2016-09-30 Biogen Ma Inc Recombinant factor viii proteins
EA201491470A1 (ru) 2012-02-15 2015-01-30 Амуникс Оперэйтинг Инк. Композиции фактора viii и способы получения и использования подобных
HUE053223T2 (hu) * 2013-06-11 2021-06-28 Cj Cheiljedang Corp L-izoleucint termelõ mikroorganizmus és eljárás L-izoleucin elõállítására annak alkalmazásával
TWI667255B (zh) 2013-08-14 2019-08-01 美商生物化學醫療公司 因子viii-xten融合物及其用途
US20160311885A1 (en) 2013-08-14 2016-10-27 Biogen Ma Inc. Recombinant factor viii proteins
US10584147B2 (en) 2013-11-08 2020-03-10 Biovertiv Therapeutics Inc. Procoagulant fusion compound
US9321812B2 (en) 2014-03-28 2016-04-26 Perle Bioscience Insulin independence among patients with diabetes utilizing an optimized hamster REG3 gamma peptide
JP6484468B2 (ja) * 2014-06-03 2019-03-13 AvanStrate株式会社 ガラス板製造方法およびガラス板製造装置
GB201410507D0 (en) * 2014-06-12 2014-07-30 Univ Bath Drug delivery enhancement agents
AU2016301303B2 (en) 2015-08-03 2021-10-07 Bioverativ Therapeutics Inc. Factor IX fusion proteins and methods of making and using same
KR20190057110A (ko) 2016-09-28 2019-05-27 코바, 인크. 치료적 mots-c 관련 펩타이드
MX2019009063A (es) 2017-01-31 2019-10-21 Bioverativ Therapeutics Inc Proteinas de fusion del factor ix y procedimientos de preparacion y utilizacion de las mismas.
MA52630A (fr) 2018-05-18 2021-05-26 Bioverativ Therapeutics Inc Procédés de traitement de l'hémophilie a

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447356A (en) * 1981-04-17 1984-05-08 Olivera Baldomero M Conotoxins
IT1190891B (it) 1982-06-24 1988-02-24 Anic Spa Metodo per la sintesi in fase solida di polipeptidi retroinvertiti
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5093317A (en) * 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
JPH0725794B2 (ja) * 1990-03-23 1995-03-22 呉羽化学工業株式会社 新規なペプチド
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US6037452A (en) 1992-04-10 2000-03-14 Alpha Therapeutic Corporation Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
DK0693924T4 (da) 1993-02-22 2008-08-04 Abraxis Bioscience Inc Fremgangsmåde til (in vivo) levering af biologiske materialer og sammensætninger, der er egnede dertil
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
EP0805864A1 (en) * 1994-12-30 1997-11-12 Seminis Vegetable Seeds, Inc. Papaya ringspot virus replicase gene
US5532153A (en) * 1995-03-23 1996-07-02 New England Biolabs, Inc. Method for cloning and producing the SacI restriction endonuclease
US7279548B2 (en) * 1996-04-03 2007-10-09 Cytogen Corporation Identification and isolation of novel polypeptides having WW domains and methods of using same
US6197526B1 (en) 1999-01-04 2001-03-06 Dyax Corp. Polypeptides for binding human factor VIII and fragments of human factor VIII
US6624289B1 (en) 1999-06-16 2003-09-23 Saint Louis University Region of factor IXa protease domain that interacts with factor VIIIa and methods therefor
US7109170B2 (en) 1999-06-16 2006-09-19 Saint Louis University Region of factor IXa protease domain that interacts with factor VIIIa and methods therefor
EP1196432A2 (en) 1999-07-02 2002-04-17 Genentech, Inc. FVIIa ANTAGONISTS
AT411997B (de) 1999-09-14 2004-08-26 Baxter Ag Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
US20020018778A1 (en) * 1999-12-06 2002-02-14 Caplan Michael J. Passive desensitization
CA2398136A1 (en) * 2000-02-08 2001-08-16 The Penn State Research Foundation Immunotherapy using interleukin 13 receptor subunit alpha 2
AU2002256518B2 (en) * 2001-05-11 2007-07-19 Research Development Foundation Inhibitors of receptor activator of NF-kappaB and uses thereof
FR2830865B1 (fr) * 2001-10-17 2004-10-22 Centre Nat Rech Scient Leurres peptidiques pour la preparation de medicaments destines a la prevention ou au traitement des pathologies auto-immunes, ou des troubles lies a l'apparition d'anticorps diriges contre des proteines exogenes
US20060204503A1 (en) * 2005-01-31 2006-09-14 Biogen Idec Ma Inc. Treatment of cancer using antibodies to polypeptides differentially expressed in human lung tumors
US20090215025A1 (en) * 2005-12-07 2009-08-27 Technische Universitat Munchen Small peptidic and peptido-mimetic affinity ligands for factor viii and factor viii-like proteins
CA2635978A1 (en) 2006-01-04 2007-07-12 Do-Coop Technologies Ltd. Solid-fluid composition
AR071478A1 (es) * 2008-04-17 2010-06-23 Baxter Healthcare Sa Peptidos de bajo peso molecular con actividad procoagulante para el tratamiento de pacientes con deficiencia de factor v (fv), fvii, fviii, fx y/o fxi

Also Published As

Publication number Publication date
EP2279200B1 (en) 2016-07-13
US8563688B2 (en) 2013-10-22
HK1154255A1 (zh) 2012-04-13
DK2279200T3 (en) 2016-08-22
JP2017019797A (ja) 2017-01-26
JP5977223B2 (ja) 2016-08-24
HK1223946A1 (zh) 2017-08-11
US10287319B2 (en) 2019-05-14
CN102007140B (zh) 2016-02-24
CA2721694A1 (en) 2009-11-12
ES2594706T3 (es) 2016-12-22
AU2009244635B2 (en) 2012-04-19
US8822638B2 (en) 2014-09-02
US20160060295A1 (en) 2016-03-03
KR20110005873A (ko) 2011-01-19
ES2739676T3 (es) 2020-02-03
CA2721694C (en) 2018-11-06
CN102007140A (zh) 2011-04-06
KR101434712B1 (ko) 2014-10-01
PL2279200T3 (pl) 2017-08-31
TW200944226A (en) 2009-11-01
CN105524163A (zh) 2016-04-27
BRPI0911203A2 (pt) 2016-07-05
JP2014074052A (ja) 2014-04-24
KR101606248B1 (ko) 2016-03-24
AU2009244635A1 (en) 2009-11-12
TWI541020B (zh) 2016-07-11
KR20130112959A (ko) 2013-10-14
PT2279200T (pt) 2016-10-12
EP3115370B1 (en) 2019-06-26
EP2279200A1 (en) 2011-02-02
AR071478A1 (es) 2010-06-23
JP2011518179A (ja) 2011-06-23
US20100022445A1 (en) 2010-01-28
NZ588200A (en) 2012-11-30
DK3115370T3 (da) 2019-07-29
JP6038452B2 (ja) 2016-12-07
US20170174724A1 (en) 2017-06-22
TW201443085A (zh) 2014-11-16
TWI573806B (zh) 2017-03-11
US9206234B2 (en) 2015-12-08
EP3115370A1 (en) 2017-01-11
US20190225648A1 (en) 2019-07-25
US10822376B2 (en) 2020-11-03
MX2010011397A (es) 2010-11-12
WO2009137256A1 (en) 2009-11-12
US20150038676A1 (en) 2015-02-05
US9598464B2 (en) 2017-03-21
US20120077749A1 (en) 2012-03-29
SG10201809286XA (en) 2018-11-29

Similar Documents

Publication Publication Date Title
HK1223946A1 (zh) 生物活性肽
HK1215182A1 (zh) 包含彈性蛋白樣肽的治療劑
EP2310407A4 (en) BIOLOGIC EFFECTIVE PEPTIDOMIMETIC MACROCYCLES
EP2275440A4 (en) GROWTH FACTOR IMITING PEPTIDES AND THEIR USE
HK1164867A1 (en) Biologically active amides
HK1213916A1 (zh) 有生物學活性的、含 -端精氨酸的肽
GB0920981D0 (en) Peptides
GB0723712D0 (en) Peptides
IL199771A0 (en) Active substance combination
GB0816976D0 (en) Protein
EP2123666A4 (en) PEPTIDE
EP2285827A4 (en) PEPTIDES AND ITS USE
HK1152717A1 (en) Angiogenic peptide
EP2254901A4 (en) THERAPEUTIC PEPTIDES
GB0703945D0 (en) Peptide
GB0920987D0 (en) Peptides
IL197675A0 (en) Peptides
GB0817978D0 (en) Peptides
GB0818627D0 (en) Protein
GB0812586D0 (en) Chimaeric peptide
GB0815673D0 (en) Peptides
GB0812093D0 (en) Phylloseptin peptides
GB0810449D0 (en) Peptides
GB0814342D0 (en) Functionalised biologically active surfaces
PL384436A1 (pl) Wibroizolator aktywny